Clinical Efficacy and Safety of Fecal Microbiota Transplantation

Keimyung University Dongsan Medical Center100 enrolled

Overview

Changes in the fecal microbiota are known to be involved in the etiology of several diseases. The purpose of this study is to evaluate the effectiveness and safety of fecal microbiota transplantation (FMT) in diseases known to be associated with intestinal microbial inbalance. .

This registry will prospectively enroll 300 patients who undergo fecal microbiota transplantation(FMT) at 3 clinical center (Yeungnam university mecial center, Kyungpook national university hospital, Keimyung university dongsan medical center). Feces received from healthy donors are prepared as frozen feces according to a standardized protocol, and transplanted to recipients within 3 months. Next generation sequencing(NGS) is used to check the characteristics of the fecal microbiota of the donor stool, and to evaluate the efficacy by checking the change in the fecal microbium of recipient before and after transplantation. The data is documented for following diseases known to be related to microbium imbalance. 1. Recurrent or Refractory CDI Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin) 2. Irritable bowel syndrome, Functional dyspepsia Abdominal symptoms questionnaires, IBS diagnosis and food-related questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin) 3. Inflammatory Bowel Disease Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), fecal calprotectin, Colonoscopic examination(Mayo endoscopic subscore, CD-SES) 4. Non-alcoholic steatohepatitis, NASH Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), BMI check 5. Obesity Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), BMI check

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Fecal Microbiota Transplantation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Those who have been diagnosed with disease to be studied and do not respond to exist treatments 1. Ulcerative colitis, Crohn disease : Patient who does not responding to anti- TNF treatment for more than 3 month. 2. Irritable bowel syndrome, Functional dyspepsia : Patient who does not responding to pharmacological therapies and serotonin uptake inhibitor for more than 6 month. 3. Recurrent of Refractory CDI, NASH, Obesity : Patient who does not responding to treatment for more than 6 month. Exclusion Criteria: * Neutrophil (\<0.5 x 10\*9/L) * Leukocytosis (\> 30.0 x 10\*9/L) * Toxic megacolon confirmed in abdomen Xray * Pregnant or lactating women

Locations (1)

KeimyungUniversity

Daegu, Jung-gu, South Korea

RECRUITING

Outcomes

Primary Outcomes

Set up a FMT registry

Set up a registry of FMT in diseases known to be associated with intestinal microbial imbalance

Time frame: 3 years

Secondary Outcomes

Patient outcome of FMT

Compare the severity of diseases, any adverse event before and after FMT

Time frame: 6 month

Developing biobank of FMT

Collect the study sample of microbium from donors and recipients

Time frame: 3 Years

Central Contacts

Yoo Jin Lee, Professor

CONTACT

+82-53-250-7163 doctorlyj@naver.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.